Neoadjuvant Chemotherapy plus Bevacizumab Combined with Total Mesorectal Excision in Treating Locally Advanced Rectal Cancer Patients with BRAF Mutation: Clinical Benefit and Safety

OBJECTIVE: To investigate clinical benefit and safety of neoadjuvant chemotherapy (NAC) plus bevacizumab combined with total mesorectal excision (TME) in treating patients with BRAF-mutated locally advanced rectal cancer (LARC). METHODS: This study included LARC patients with BRAF mutation admitted...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Jintian, Wang, Yi, Yu, Hui, Zheng, Liang, Cai, Xiongchao, Chen, Yigui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8677386/
https://www.ncbi.nlm.nih.gov/pubmed/34925539
http://dx.doi.org/10.1155/2021/4227650

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8677386/
https://www.ncbi.nlm.nih.gov/pubmed/34925539
http://dx.doi.org/10.1155/2021/4227650

Ejemplares similares